How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
EMEA Pharmacy Retailing Market
- By Store Format: Chain Pharmacies, Independent Pharmacies, Hospital Pharmacies, Online Pharmacies, Specialty Pharmacies
- By Product Category: Prescription Medicines, Over-the-Counter (OTC) Drugs, Health and Wellness Products, Personal Care Products, Medical Devices and Supplies
- By Customer Segment: Retail Consumers, Healthcare Professionals, Institutional Buyers, Senior Citizens, Chronic Disease Patients
- By Distribution Channel: Brick-and-Mortar Stores, E-commerce Platforms, Direct-to-Consumer Delivery, Wholesale Distribution
- By Ownership Type: Corporate-Owned Pharmacies, Franchise Pharmacies, Privately Owned Pharmacies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Chain Pharmacies leads By Store Format at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 296 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.181 →
- 12 Company Profiles 14 players: SWOT & benchmarking p.189 →
Full report · locked preview
Everything inside the EMEA Pharmacy Retailing Market report
A complete, evidence-based study - 12 chapters and 124 sections covering market size, segmentation across 5 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Store Format 5
Product Category 5
Customer Segment 5
Distribution Channel 4
Ownership Type 3
Companies profiled
Alliance Boots (now part of Walgreens Boots Alliance)
Phoenix Group
Celesio AG (now part of McKesson Europe)
McKesson Europe
Walgreens Boots Alliance
Zur Rose Group
Medipal Holdings Corporation (operates in EMEA through partnerships)
Dm-drogerie markt (DM)
LloydsPharmacy (part of Celesio)
Apoteket AB
Farmacias Ahumada (operates in EMEA through partnerships)
Uniphar Group
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Alliance Boots (now part of Walgreens Boots Alliance)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Phoenix Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Celesio AG (now part of McKesson Europe)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →McKesson Europe
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Walgreens Boots Alliance
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Zur Rose Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Medipal Holdings Corporation (operates in EMEA through partnerships)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Dm-drogerie markt (DM)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →LloydsPharmacy (part of Celesio)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Apoteket AB
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Farmacias Ahumada (operates in EMEA through partnerships)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Uniphar Group
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Europharm Group
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Mediq
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,889M by 2033 · 5.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Chain Pharmacies42.4
- Independent Pharmacies13.9
- Hospital Pharmacies16.4
- Online Pharmacies9.6
- Specialty Pharmacies17.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,230M → $2,147M · 7.2%
Europe$857.3M → $1,284M · 5.2%
Asia Pacific$782.7M → $1,122M · 4.6%
Latin America$484.5M → $741.9M · 5.5%
Middle East and Africa$372.7M → $632.7M · 6.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.832026
5.852027
5.862028
5.882029
5.882030
5.912031
5.912032
5.922033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Alliance Boots (now part of Walgreens Boots Alliance)14.1
- Phoenix Group18.3
- Celesio AG (now part of McKesson Europe)12.4
- McKesson Europe10.7
- Walgreens Boots Alliance8.1
- Zur Rose Group8.4
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Store Format28.6%
Product Category14.3%
Customer Segment31.3%
Distribution Channel13.2%
Ownership Type12.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America36.2
- Europe21.7
- Asia Pacific18.9
- Latin America12.5
- Middle East and Africa10.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Alliance Boots (now part of Walgreens Boots Alliance) | 74 | 78 | 79 | 74 | 93 | 73 | 79 |
| Phoenix Group | 90 | 71 | 88 | 93 | 80 | 70 | 82 |
| Celesio AG (now part of McKesson Europe) | 78 | 69 | 73 | 71 | 68 | 81 | 73 |
| McKesson Europe | 62 | 59 | 66 | 64 | 66 | 60 | 63 |
| Walgreens Boots Alliance | 68 | 72 | 76 | 68 | 67 | 64 | 69 |
| Zur Rose Group | 67 | 69 | 52 | 70 | 60 | 62 | 63 |
| Medipal Holdings Corporation (operates in EMEA through partnerships) | 56 | 59 | 65 | 53 | 58 | 61 | 59 |
| Dm-drogerie markt (DM) | 43 | 59 | 35 | 43 | 41 | 54 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Alliance Boots (now part of Walgreens Boots Alliance)
- Phoenix Group
- Celesio AG (now part of McKesson Europe)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Alliance Boots (now part of Walgreens Boots Alliance) | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Phoenix Group | ✓ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Celesio AG (now part of McKesson Europe) | ◐ | ✓ | ✓ | ◐ | ◐ | ◐ |
| McKesson Europe | ◐ | − | ◐ | ◐ | ✓ | ◐ |
| Walgreens Boots Alliance | ◐ | ✓ | ◐ | ◐ | ◐ | − |
| Zur Rose Group | ✓ | ◐ | ◐ | ◐ | ◐ | − |
| Medipal Holdings Corporation (operates in EMEA through partnerships) | − | − | ◐ | ◐ | ◐ | ◐ |
| Dm-drogerie markt (DM) | − | ◐ | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Phoenix Group82
2Alliance Boots (now part of Walgreens Boots Alliance)79
3Celesio AG (now part of McKesson Europe)73
4Walgreens Boots Alliance69
5McKesson Europe63
6Zur Rose Group63
7Medipal Holdings Corporation (operates in EMEA through partnerships)59
8Dm-drogerie markt (DM)46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Alliance Boots (now part of Walgreens Boots Alliance)Phoenix Group
Challenger2
Strong scale, closing on the leaders.
Celesio AG (now part of McKesson Europe)Walgreens Boots Alliance
Contender3
Focused players with pockets of strength.
McKesson EuropeZur Rose GroupMedipal Holdings Corporation (operates in EMEA through partnerships)
Niche1
Specialists in a single segment or region.
Dm-drogerie markt (DM)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Store Format in North America, then scale across EMEA Pharmacy Retailing Market — a $382M beachhead inside a $6.06B market.
Beachhead (SOM)$382Mobtainable near-term
Serviceable (SAM)$2.22Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Chain Pharmacies
Best fit — highest urgency & budget in Store Format.
Economic buyer80 fit
Independent Pharmacies
Strong fit — clear ROI and a fast path to value.
End user65 fit
Hospital Pharmacies
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Store Format in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Product Category & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Customer Segment
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel29%
Digital / self-serve20%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Store Format leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win EMEA Pharmacy Retailing Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified24%
Evaluation13%
Closed-won5%
$8.8KCAC
$45KLTV
5.1:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
EMEA Pharmacy Retailing Market is a durable-growth opportunity — $9.10B by 2033, compounding at 7.2%.
TAM · 2025$5.20Btoday
TAM · 2033$9.10Bforecast
CAGR7.2%2027–2033
Cumulative$63.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$9.10BTotal addressable market
SAM$3.47BServiceable available market
SOM$707MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.2% CAGR
Demand compounds through 2033, outpacing GDP across Store Format.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Store Format moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$9.10BLarge & growingTAM by 2033 at 7.2% CAGR
$3.47BServiceable nowreachable with today’s model
$707MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.10BBear4.7% CAGR
$9.10BBase7.2% CAGR
$11.7BBull9.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Product Category optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
EMEA Pharmacy Retailing Market — a $7.41B market by 2033. Plan: grow share from 6.5% to 13.5%.
Market size · 2033$7.41Btotal addressable
Market CAGR8.9%2027–2033
Target share13.5%from 6.5% today
Revenue ambition$1.00Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.5% | 13.5% | On track |
| Revenue | $476M | $1.00B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 32.0% | 38.7% | On track |
| Customer retention | 90.7% | 92.9% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Store Format
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Product Category capability
A defensible second engine — invest in Product Category to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Store Format share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Product Category
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $145M capacity & capability investment
- Greenlight bolt-on M&A in Product Category
- Authorise North America expansion plan
- Fund R&D program for Store Format leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossBehind
- Input-cost & supply riskAhead
- Regulatory / policy changeBehind
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the EMEA Pharmacy Retailing Market conversation — a $1.93B market you can size, segment and defend in minutes.
Market size · 2033$1.93Btotal opportunity
Growth5.9%CAGR to 2033
Addressable buyers1,771+accounts in scope
Typical ROI4.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Store Format
Goal Grow share in Store Format
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.6×return on cost, year one
< 3 mopayback period
$100K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
Alliance Boots (now part of Walgreens Boots Alliance)Phoenix GroupCelesio AG (now part of McKesson Europe)McKesson EuropeWalgreens Boots AllianceZur Rose GroupMedipal Holdings Corporation (operates in EMEA through partnerships)Dm-drogerie markt (DM)+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your EMEA Pharmacy Retailing Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
EMEA Pharmacy Retailing Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →EMEA Phosphonate Market
Market size, share, segmentation and regional forecast.
$913M market · 2025 base year
View reportEMEA PID (Photoionization Detection) Sensors and Detectors Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportEMEA Piperonyl Butoxide Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportEMEA Planter Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportEMEA Plethysmograph Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportEMEA Plywood Market
Market size, share, segmentation and regional forecast.
$834M market · 2025 base year
View reportEMEA Poly Aluminium Chloride Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportEMEA Polyamide 6,6 Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportEMEA Polyphthalamide (PPA) Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportEMEA Pool Alarms Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportEMEA Power Electronics for Electric Vehicles Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportEMEA Premium Motorcycle Helmets Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.